Study identifier:D0520C00012
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A 12-week, randomised, double-blind, placebo-controlled, parallel group, multinational, phase IIb dose range finding study to evaluate the efficacy and safety of AZD9668 administered orally at 3 dose levels to patients with Chronic Obstructive Pulmonary Disease (COPD) on treatment with tiotropium
Chronic Obstructive Pulmonary Disease
Phase 2
No
AZD9668, AZD9668 Placebo
All
838
Interventional
40 Years - 80 Years
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verified 01 Jun 2012 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The primary objective is to evaluate the dose-response relationship and efficacy of AZD9668 at 3 dose levels compared with placebo in symptomatic COPD patients by assessing effects on lung function and symptoms of COPD.
Location
Location
ADELAIDE, SA, Australia
Location
CARINA HEIGHTS, QLD, Australia
Location
CONCORD, NSW, Australia
Location
DAW PARK, SA, Australia
Location
GLEBE, NSW, Australia
Location
KOGARAH, NSW, Australia
Location
NEDLANDS, WA, Australia
Location
PARKVILLE, VIC, Australia
Arms | Assigned Interventions |
---|---|
Active Comparator: 1 AZD9668 active treatment | Drug: AZD9668 2 x 30 mg oral tablets twice daily (bid) for 12 weeks |
Active Comparator: 2 AZD9668 active treatment | Drug: AZD9668 2 x 10 mg oral tablets twice daily (bid) for 12 weeks |
Active Comparator: 3 AZD9668 active treatment | Drug: AZD9668 2 x 2.5 mg oral tablets twice daily (bid) for 12 weeks |
Placebo Comparator: 4 AZD9668 placebo treatment | Drug: AZD9668 Placebo 2 x Matched placebo to oral tablet twice daily (bid) for 12 weeks |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.